India is now known as the ‘pharmacy of the world’ as it produces one third of the world’s biopharma products. In this article in Express Pharma Online Allan Schouten, PM Group Managing Director for Asia talks about the growth of the Indian pharma market and the need to hire a consultant when developing a new industrial plant.
India is a preferred location for pharma activities, with affordable R&D and drug production facilities. There are currently approximately 125 US FDA and nearly 90 UK MHRA approved pharma manufacturing plants in India and the IMS estimates that the market will have an annual sales growth of 14 to 17% through to 2014. As a result of this growth curve, many companies are investing huge amounts to build new infrastructure and upgrade existing facilities.
As it is necessary to comply with regulatory requirements set by bodies such as the US FDA, the European Medicines Agency (EMEA) and other national boards, Schouten explains that it is advisable to hire a consultant with the right mix of process expertise and international capabilities. He continues to explain how PM Group brings international experience with local knowledge to deliver complex projects such as GSK Biologicals vaccines facility in Singapore and Dr. Reddy’s Laboratories campus in Hyderabad, India.
Click here to read the full article on expresspharmaonline